CX717 was created by Dr Gary Lynch from the University of California. CX717 is part of a family of compounds called ampakines which work by boosting the brain chemical glutamate responsible for learning and recall.
In 2005 The U.S. Food and Drug Administration (FDA) accepted Cortex Pharmaceuticals' IND (Investigational New Drug) application to initiate pilot Phase II clinical trials in the United States.